演題詳細

ポスター / Poster

ポスター 26 (Poster 26) :B細胞性リンパ腫:Chemotherapy

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
塚本 憲史 (Norifumi Tsukamoto):1
1:群馬大学医学部附属病院 腫瘍センター
 
前へ戻る

Clinical outcome of radioimmunotherapy with ASCT (Z-LEED) for B-cell lymphoma

演題番号 : PS-1-191

辰巳 陽一 (Yoichi Tatsumi):1、頼 晋也 (Shinya Rai):1、金井 良高 (Yoshitaka Kanai):1、平瀬 主税 (Chikara Hirase):1、山口 晃文 (Terufumi Yamaguchi):1、森田 泰慶 (Yasuaki Morita):1、田中 宏和 (Hirokazu Tanaka):1、嶋田 高広 (Takahiro Shimada):1、宮武 淳一 (Junichi Miyatake):1、芦田 隆司 (Takashi Ashida):1

1:Department of Hematology, Kinki Univ., Japan

 

BACKGROUND: Rarioimmunotherapy (RIT) with 90yttrium ibritumomab tiuxetan (90Y-IT) is known to be an effective approach for treatment of NHL. 3-year PFS in our department is 39.1% (OS 79.9%), which is not sufficient considering the cost of RIT. Thus, we employed RIT (90Y-IT) followed by HDT in patients with relapsed and refractory B-cell lymphoma. In this report, we tried to evaluate the safety and efficacy of RIT using ibritumomab tiuxetan (Zevalin) combined with high-dose LEED chemotherapy and ASCT (Z-LEED) in refractory/relapsed B-cell lymphoma. PATIENTS AND METHODS: Eight patients with relapsed or refractory B-cell lymphoma (three mantle cell lymphoma patients and five grade III FL/DLBCL patients) were treated with Z-LEED. After PBSC mobilization and harvesting, patients were given rituximab 250 mg/m2 followed by 90Y-IT (14.8 MBq/kg) on day -14 before ASCT with LEED (500 mg/m2 etoposide, 60 mg/m2 cyclophosphamide, 130mg/m2 mephalan, and 40 mg/m2 dexamethasone). RESULTS: Two patients had received more than tree prior treatments, and three had chemotherapy-resistant disease. There were no therapy-related deaths. While one patient with conventionally measurable disease at the time of treatment, the respective complete and overall response rates were 100%. Seven patients remain CR at 2 to 27 months from transplantation and 8 to 102 months from diagnosis. One patient relapsed after four months from transplantation. CONCLUSION: ibritumomab tiuxetan combined with LEED high-dose chemotherapy is safe and possibly effective as a conditioning regimen for ASCT.

前へ戻る